-+ 0.00%
-+ 0.00%
-+ 0.00%

Genenta Science Collaborates With Anemocyte For Manufacturing Critical Starting Materials For Cutting-Edge Cell-Based Therapies

Benzinga·05/07/2025 11:06:33
Listen to the news

Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a collaboration with Anemocyte, a leading Biotech Manufacturing Organization (BMO) based in Italy. This strategic partnership marks a major milestone, encompassing the successful production of critical starting materials, including the establishment of Cell Banks and the manufacturing of Plasmids for viral vector production.

This collaboration represents a pivotal step in the advancement of immuno-oncology therapies, highlighting the powerful synergy between Genenta's innovative platform and Anemocyte's proven expertise in the production of high-quality starting materials.